Background Type 2 diabetes mellitus (T2DM) is a condition characterized by insulin resistance and progressive failure of the insulin-secreting beta-cells. Based on studies in small cohorts of young patients (especially Pima Indian offspring), we know that individuals with childhood onset T2DM are at very high risk for diabetes-related morbidity and mortality, due to a longer life-time duration of diabetes, as well as possible increased rapidity of beta-cell failure. Our primary study objective is to acquire data on the natural history of T2DM in youth. Measurements will include indices of beta-cell function, body composition, cardiovascular disease risk factors, gut hormones, and psychological well-being. These data will be compared to findings in non-diabetic volunteers who are lean or overweight/obese. Data from several recent epidemiologic studies have indicated a link between diet soda consumption, obesity, and even type 2 diabetes. However, there is no evidence for a causal relationship. Artificial sweeteners have long been regarded as metabolically inert substances since they contain no or very few calories. Yet, data from rodent studies show that artificial sweeteners may have distinct effects on glucoregulatory hormones and our previous pilot study has confirmed a greater responsiveness of GLP-1 when a glucose meal was preceded by diet soda. We plan to further characterize effects of consumption of artificial sweeteners on intestinal and will enroll healthy volunteers, as well as subjects with type 1 and type 2 diabetes. These subjects will undergo repeated oral glucose tolerance tests or mixed meal tests, preceded by consumption of a water or a sucralose-containing diet soda. We will investigate differences in insulin, glucose, or other hormone levels between the repeated tests.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2011
Total Cost
$576,464
Indirect Cost
City
State
Country
Zip Code
Sylvetsky, Allison C; Issa, Najy T; Chandran, Avinash et al. (2017) Pigment Epithelium-Derived Factor Declines in Response to an Oral Glucose Load and Is Correlated with Vitamin D and BMI but Not Diabetes Status in Children and Young Adults. Horm Res Paediatr 87:301-306
Brown, Rebecca J; Meehan, Cristina Adelia; Cochran, Elaine et al. (2017) Effects of Metreleptin in Pediatric Patients With Lipodystrophy. J Clin Endocrinol Metab 102:1511-1519
Gourgari, Evgenia A; Mete, Mihriye; Sampson, Maureen L et al. (2017) Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes. Diabetes Care 40:e88-e89
Blau, Jenny E; Tella, Sri Harsha; Taylor, Simeon I et al. (2017) Ketoacidosis and SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev :
Brown, Rebecca J; Araujo-Vilar, David; Cheung, Pik To et al. (2016) The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 101:4500-4511
Brehm, Anja; Liu, Yin; Sheikh, Afzal et al. (2016) Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 126:795
Blau, J E; Abegg, M R; Flegel, W A et al. (2015) Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade. Am J Transplant 15:2995-3001
Taylor, Simeon I; Blau, Jenny E; Rother, Kristina I (2015) SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 100:2849-52
Taylor, Simeon I; Blau, Jenny E; Rother, Kristina I (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8-10
Sarkar, Gayatri; Alattar, May; Brown, Rebecca J et al. (2014) Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670. Diabetes Care 37:e219-20

Showing the most recent 10 out of 37 publications